Skip to main content

Table 3 The results of the base case analyses comparing timing of price negotiations

From: The impact of early phase price agreements on prices of orphan drugs

   Spinraza    Orkambi   
Actual price   € 240.000    € 169,386   
Cost of capital   9% 7% 5% 9% 7% 5%
> Phase III BE price € 203,449 € 181,040 € 160,202 € 143,589 € 127,774 € 113,066
Change −15.2% −24.6% −33.2% −15.2% − 24.6% − 33.2%
>Phase II BE price € 188,394 € 159,123 € 133,553 € 132,964 € 112,305 € 94,259
Change − 21.5% −33.7% −44.4% −21.5% − 33.7% −44.4%